TW202319054A - Nlrp3調節劑 - Google Patents

Nlrp3調節劑 Download PDF

Info

Publication number
TW202319054A
TW202319054A TW111124256A TW111124256A TW202319054A TW 202319054 A TW202319054 A TW 202319054A TW 111124256 A TW111124256 A TW 111124256A TW 111124256 A TW111124256 A TW 111124256A TW 202319054 A TW202319054 A TW 202319054A
Authority
TW
Taiwan
Prior art keywords
membered
alkyl
ring
pharmaceutically acceptable
solvate
Prior art date
Application number
TW111124256A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆士 柯林斯
文克 波盧
申東 元
約翰 那斯
Original Assignee
英商佐馬根生物有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商佐馬根生物有限公司 filed Critical 英商佐馬根生物有限公司
Publication of TW202319054A publication Critical patent/TW202319054A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111124256A 2021-06-29 2022-06-29 Nlrp3調節劑 TW202319054A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163216446P 2021-06-29 2021-06-29
US63/216,446 2021-06-29
US202263320155P 2022-03-15 2022-03-15
US63/320,155 2022-03-15

Publications (1)

Publication Number Publication Date
TW202319054A true TW202319054A (zh) 2023-05-16

Family

ID=84692056

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111124256A TW202319054A (zh) 2021-06-29 2022-06-29 Nlrp3調節劑

Country Status (5)

Country Link
US (1) US20240327413A1 (cg-RX-API-DMAC7.html)
EP (1) EP4362946A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024529839A (cg-RX-API-DMAC7.html)
TW (1) TW202319054A (cg-RX-API-DMAC7.html)
WO (1) WO2023278438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
TW202231281A (zh) * 2020-12-25 2022-08-16 大陸商上海拓界生物醫藥科技有限公司 一類含噠嗪的化合物及其醫藥用途
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
PL4363406T3 (pl) 2021-07-02 2026-01-05 Astrazeneca Ab Inhibitory inflamasomu nlrp3
CA3226995A1 (en) * 2021-07-21 2023-01-26 Nico Therapeutics, Inc. Annulated pyridazine compound
IL310992A (en) * 2021-08-25 2024-04-01 Ptc Therapeutics Inc NLRP3 inhibitors
CN118302417A (zh) * 2021-08-25 2024-07-05 Ptc医疗公司 Nlrp3抑制剂
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技(浙江)有限公司 一种含氮化合物、其制备方法及应用
CN118234730A (zh) * 2021-11-17 2024-06-21 豪夫迈·罗氏有限公司 杂环nlrp3抑制剂
EP4499646A4 (en) * 2022-03-31 2026-03-18 Hangzhou Highlightll Pharmaceutical Co Ltd NLRP3 Inflammasome Inhibitors
WO2024006559A1 (en) * 2022-07-01 2024-01-04 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
JP2025524640A (ja) * 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
CN120569372A (zh) * 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
EP4658649A1 (en) * 2023-01-31 2025-12-10 Janssen Pharmaceutica NV [1,2,4]triazolo[4,3-a]pyridines and [1,2,4]triazolo[4,3-a]pyrazines as nlrp3 inhibitors
JP2026504422A (ja) 2023-01-31 2026-02-05 ヤンセン ファーマシューティカ エヌ.ベー. NLRP3阻害剤としてのピロロ[1,2-d][1,2,4]トリアジン及びピラゾロ[1,5-d][1,2,4]トリアジン
WO2024160692A1 (en) * 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv Imidazo[1,2-d][1,2,4]triazines as nlrp3 inhibitors
TW202448892A (zh) * 2023-04-17 2024-12-16 大陸商上海拓界生物醫藥科技有限公司 稠合噠嗪類衍生物及其用途
AU2024280075A1 (en) 2023-06-02 2025-12-11 Merck Sharp & Dohme Llc 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2026082103A1 (zh) * 2024-10-16 2026-04-23 青岛博森泰科技有限公司 一种nlrp3抑制剂用于预防和/或治疗与体重增加相关的疾病或病症的用途
WO2026082092A1 (zh) * 2024-10-16 2026-04-23 青岛博森泰科技有限公司 一种nlrp3抑制剂用于治疗炎症的用途
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919957D0 (en) * 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1745039A4 (en) * 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021009567A1 (en) * 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Nlrp3 modulators
CN118302417A (zh) * 2021-08-25 2024-07-05 Ptc医疗公司 Nlrp3抑制剂

Also Published As

Publication number Publication date
EP4362946A4 (en) 2025-05-21
EP4362946A1 (en) 2024-05-08
US20240327413A1 (en) 2024-10-03
JP2024529839A (ja) 2024-08-14
WO2023278438A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
WO2023278438A1 (en) Nlrp3 modulators
JP7595642B2 (ja) Nlrp3モジュレーター
US11603375B2 (en) NLRP3 modulators
AU2020312800B2 (en) N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (ms)
CA3255244A1 (en) NLRP3 MODULATORS
KR20080110905A (ko) 테레프탈라메이트 화합물 및 조성물, 및 hiv 인테그라제억제제로서의 그들의 용도
JP2023513373A (ja) P2x3修飾薬
CN117881401A (zh) Nlrp3调节剂
WO2025059069A1 (en) Nlrp3 modulators
JP2011508758A (ja) N−フェニルイミダゾ[1,2−α]ピリジン−2−カルボキサミド誘導体、これらの調製およびこれらの治療用途
WO2025064325A1 (en) Gpr35 modulators
EA049038B1 (ru) Модуляторы nlrp3